Free Newsletter
Amgen bone drug gets NICE thumbs up
Free newsletter via e-mail
Tools
It's another victory for Amgen with its new drug Prolia. The U.K.'s cost-effectiveness watchdog has recommended use of the bone treatment by the National Health Service, in women at risk of fractures who can't take existing drugs. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: